A Systematic Review on Ovarian Cancer

Faheem Shehzad [a,✉],Sidra Naseem[a], and Attia Irum[b]

[a]Department of Computer Science, COMSATS University Islamabad, Wah Campus, Wah Cantt, Pakistan

[b]Department of Computer Engineering EME college NUST, Islamabad, Pakistan

✉, [a] Farishehzad92@gmail.com
[a] Department of Computer Science, Comsats University Islamabad, Wah Campus, Wah Cantt, Pakistan

ABSTRACT

Most women suffer late-stage ovarian disease endure a high pace of mortality. It is required to identify and analyze cancer right on time in its initial phase of development. It is generally suggested clinical screening of women through different detection techniques like imaging modalities (ultrasound, CT scan, MRI) and also detection using different biomarkers for cancer symptoms existing in patient's blood. Biomarker, a distinguished device that are available for patients with ovarian malignant growth, the particular one is cancer anigen CA-125, is usually tried for medical use which is supposed to be more efficient biomarker to detect the infection. Here, we depict elective biomarkers like CA-125 which conquer a significant number of the issues related to malignancy, for example, expanded affectability and specificity, particularly in the beginning phases of ovarian cancer, and which could be utilized effectively in a biosensor design.

Keywords: *Ovarian cancer, Imaging modalities, Biomarker, Biosensor*

1 INTRODUCTION

Nowadays, different types of cancers have become a serious medical issue all over the world in which females aged 50 or greater are affected the most. Ovarian cancer is one of the most dangerous types of cancer which originates in the ovaries[1]. The death ratio due to ovarian cancer is higher than the other gynecological cancers like breast cancer or liver cancer.

Each year reported cases of this disease about 225,000 and approximately 140,000 women die due to this [2]. Ovarian cancer is less likely to be diagnosed in a younger female than elder females. Since 1995, it is roughly estimated that the ratio of survival rate of women due to ovarian cancer is very less than the other gynecological cancers [1, 3]. It is also estimated that women with this cancer diagnosed during the first year, their survival chance is increased by 40 percent instead of when it is diagnosed after five years [4]. Since 1970s the endurance rates for ovarian malignant growth have improved a little due to significant advances in ovarian cancer surgery and treatment [5, 6]. Most cases determined to have ovarian cancer growth are now indicating late-stage infection (70% of cases)[1, 7]. Fig. 1 shows the overview of this survey.

2 SYMPTOMOLOGY

In the initial stage ovary cancer frequently presents with a small number of symptoms and at later stages, it shows vague symptoms. The indications of this disease included nausea, bloating, back pain, trouble eating, and urinary earnestness, which will in general decline and persevere as the ovarian malignant growth advances [8]. As mentioned above these symptoms don't shows until the later phases of cancer. It is much more difficult to detect this disease early because there are no actual symptoms of cancer present in women. Ovary cancer displays as adnexal lesions, these lesions are rarely malignant and generally normal [9]. Around about 1% of females who are affected by adnexal masses become malignant, and it is critical to keep away unnecessary involvement for the remaining majority [10]. Fig. 2 shows the symptoms of ovarian cancer.



Fig. 1. Overview of Survey



Fig. 2. Showing Symptoms of Ovarian Cancer [9].

Before proceeding with further testing like biopsies, it is necessary to build up the nature of these lesions by image detection procedures. Fig. 3 shows the death rate of females over 50, their reason for death, and their country's level of income.



Fig. 3. Shows the Death Rate of Females Over 50, their Rason for Death, and Their Country's Level of Income [10].

3 CLASSIFICATION OF OVARIAN CANCERS

Here further classification of Ovary cancer. Fig. 4 shows all types of ovary cancer.



Fig. 4. Shows all Types of Ovary Cancer.

3.1 EPITHELIAL CANCERS

Cancers of surface epithelial inception comprise around 66% of every ovarian neoplasm and a significantly more prominent extent of ovary-threatening neoplasms. These cancers can occur overwhelmingly in adults, through the threatening structures for the most part showing up sometime later. These cancers are characterized by concurring the dominating example of separation of the cancer cells [11].

3.2 EPITHELIAL CANCERS

These cancers are the most common type of cancer. Visibly, serous cystadenoma is regularly a unilocular growth, loaded up with serous liquid and having a smooth surface and comprises a multilocality of sores. Adenofibroma is a dominatingly strong stringy cancer. Serous cancer is often bilateral and usually large. It displays a mixture of solid growth shapes, papillary and cystic. Cancer regularly attacks through the ovary and becomes outside of the ovarian surface[12, 13].

3.3 MUCINOUS CANCERS

Mucinous cancer was accepted to comprise around 12% of ovarian distortions. In any case, ongoing assessments show the genuine frequency to be at around 3% [14-16]. It is perceived that a Mucinous tumor is a different substance from all other epithelial tumors. It has a particular characteristic history, chemosensitivity, molecular profile, and visualization in contrast with high-grade serous tumors. The mucinous tumor is the most regular histological subtype in ladies younger than 40. The main conceivable danger factor corresponding with Mucinous tumors is tobacco smoking [17].

3.4 ENDOMETRIOID CANCERS

Endometrioid cancer is presently viewed as an uncommon analysis in numerous focuses, it remains analyzed at higher recurrence in different focuses [13, 18]. At present, this doesn't affect clinical administration, as patients likely to have high-grade ovarian tumors get a similar treatment paying little mind to histotype [19, 20]. In any case, as our comprehension of the fundamental pathogenesis of ovarian tumors extends, including depicting the varying cell heredities and atomic modifications over histotypes, histotype-explicit treatment ways to deal with ovarian tumors are probably going to arise, requiring precise classification [21].

For the situation of high-grade serous tumor, it is currently realized that the forerunner lesion most generally starts in the fallopian tube, though endometrioid tumor emerges from endometriosis [22-24].

3.5 CLEAR CELL CANCERS

Among harmful epithelial cancer of the ovary, clear cell tumors, just as endometrioid adenocarcinoma, are most oftentimes related to ovarian endometriosis [25]. The recurrence of endometriosis is allegedly somewhere in the range of 21% and 54% in the enormous arrangement of clear cell tumors [26]. Numerous studies have unequivocally proposed a harmful change of endometriosis to clear cell tumors, however minimal atomic proof exists to help the thought that endometriosis is the antecedent of clear cell tumors.

3.6 CARCINOSARCOMA

Carcinosarcoma is an uncommon malignancy representing just 1 to 5% of every ovary tumor. These cancers have both carcinomatous and sarcomatous components. This type has related to advanced steps of metastatic illness and helpless visualization when contrasted and other types of epithelial malignancies. Many females suffer from ovarian carcinosarcoma backslide within 1 year after the culmination of beginning treatment, with a median endurance time going from eight to twenty-six months [27, 28]. The treatment of ovarian carcinosarcoma depends to a great extent on information from little case arrangement and the administration of other types of epithelial tumors. The current treatment for ovarian carcinosarcoma is platinum-based chemotherapy [29]. The 5-year survival rate in females due to carcinosarcoma is shown in Table 1.

Table 1. Survival rate (5 years) in females due to carcinosarcoma cancer[30].

Stages	Survival rate (5 years)
I	74.12% (65.09%–83.16%)
II	50.02% (39.72%–61.29%)
III	23.98% (20.01%–28.10%)
IV	12.79% (8.62%–19.27%)

3.7 BRENNER CANCERS

Considerate, fringe, and threatening Brenner tumor of the ovary minutely take after urothelial and its neoplasm.As indicated by the amended World Health Organization(WHO) ovarian tumor grouping, they form a particular subgroup of epithelial ovarian tumors, speaking to be one percent of all ovarian neoplasms [31, 32].

4 MATERIAL AND METHODS

To get information on different types uses different modalities of imaging, there are two different imaging methods, first type is anatomic imaging like transvaginal ultrasonography (TUS), MRI, CT, and ultrasound to create detailed maps of organ architecture. The second type is molecular imaging like SPECT, OPTICAL imaging, and PET provide detailed functional information on the biochemistry of the organ tissues [33]. Early stages of cancer lesions show different qualities to late-stage and threatening lesions, which can be seen by transvaginal ultrasonography [34]. Magnetic resonance imaging(MRI) displays the differences between malignant and benign lesions. Ovarian malignancy can be exceptionally hard to identify due to the profundity of the cancers inside the body, and the characteristic or then again obscure signs outlined before

[35]. Hence, it is regularly the situation that it isn't searched for by ladies until their side effects have advanced, which is for the most part when the malignant growth has arrived at later stages [36].

4.1.1 ULTRASOUND

Ultrasound utilizes sound waves to make a picture on a computer screen. Sound waves are delivered from a little test set in the woman's vagina and a little receiver-like instrument canceled a transducer gives sound waves and gets the echoes as they skip off organs [37]. A PC transforms these echoes into a picture on the screen. It is regularly the main test done if any problem with the ovary is supposed. It tends to be utilized to locate an ovarian malignant and to check if it is a strong lesion or a liquid-filled swelling. It can be utilized to improve take a gander at the ovary to perceive how giant it is and what it looks like inside. This enables the specialist to choose which lesions are more troubling [38].

4.1.2 MRI

Additional imaging can include an MRI test, which is a ground-breaking test device for deciding whether adnexal lesions are threatening, because of morphological contrasts delineated beforehand[39]. It has a lot of advanced explicitness also, precision for deciding a lesions nature than (TUS), with an accuracy of 84 percent against 40 percent for TUS, and having an exactness of 89 percent against 64 percent for (T U S)[40, 41].

4.1.3 CT SCANS

The CT examination is an x-beam test that makes itemized cross-sectional pictures of your body. The test can help advise if ovarian malignant growth has spread to different organs. CT filters do not show little lesions well, however, they can see larger lesions, and might have the option to check whether the cancer is developing into close-by structures. A CT output may likewise discover augmented lymph hubs, indications of lesions growth spread to the liver or other different organs, or signs that cancer is influencing your bladder or kidneys.

4.2. DETECTION USING BIOMARKER

Biomarkers started, in 1980 and are characterized by The National Cancer Centre as "a natural particle originating in blood, other body tissues, or liquids that is an indication of an ordinary or strange cycle or a condition or illness". The ID furthermore, sure, measurement of clinically significant biomarkers is a quickly developing territory of exploration. Regarding malignancy biomarkers, the location of the existence of that particles is urgent in the wording of diagnosing the phase and nature of a specific illness state and also, observing its movement impacted by the understanding of its treatments. The selection of biomarkers for ovarian cancer is shown in (Table 3). The main current broadly utilized biomarkers for ovary distortion is the notable disease (CA-125) measure, which are utilized in checking licenses for more than thirty years. This antigen is financially delivered and it can be bought[42]. The radiation of bound particles is estimated and is relative to the grouping of this antigen in the example. Tests, for example, are utilized both clinically, and in examination[43]. Table 3 shows the different biomarkers selected by the researchers.

Table 3. Selection of biomarkers for ovarian cancer

References	Ovarian Cancer Biomarker	Method	SE	SP
[44]	CA- 125	CA-125 with immunoassay	82%	67.2%
[45]	CA- 125 WITH TTR AND APOA-1	Immunoturbimetry & Chemiluminescence	91.6%	92.4%
[46]	HE4	DNA & PCR	73%	94.9%

[47, 48]	Osteopontin	Immunohistochemistry & PCR	82%	35%
[49, 50]	HSP – 27	Glycotranscriptome analysis	-	-
[51, 52]	LPA	Capillary Electrophoresis	98.2%	90.1%
[43]	Mesothelin	ELISA	61%	97.9%

4.3. DETECTION USING BIOSENSOR

Till now there have been generally couple of works that depict the creation of biosensors for the discovery and test of a biomarker for ovary malignant growth [53, 54]. A number showed up in the arrangement with endeavors to place the CA-125 measure depicted above into a sensor design, despite the suspicious potential offered for beginning phase identification by this biomarker[42].

4.4. OVARIAN CANCER DETECTION USING DEEP LEARNING METHODOLOGIES

In [55] design Deep Interactive Learning with a pre-trained segmentation model on a publicly available large dataset of cancer and non-cancer. After training further annotation can reduce the time. The overcome of this proposed method interaction over union is 0.74, recall 0.86, and precision 0.84. In [56] proposed a CNN-based segmentation model with the combination of GLCM contourlet transformation and CNN feature extraction method. The proposed method contains four steps preprocessing, segmentation, selecting the best feature extraction in the last optimization or classification and these steps perform on ovarian ultrasound images data. [57] introduced a weakly supervised learning model on different datasets and through algorithms achieve high accuracy, precision, recall, and f-measure. [58] trained their model on CT images and the dataset was manually labeled. Performed different segmentation methods and achieve better results. In [59] designed IEDLOVD (IE with a deep learning-based ovarian tumor diagnosis) method was due to this improved image quality, then improve optimization through BWOA (black widow optimization algorithm) and used some feature extraction and classification techniques to maximize precision and recall rate. In [60] some previous AI methods are compare with for the detection of cancer and compare the results. In [61] segment of the ovarian cyst then use LBP for feature extraction and SVM for classification to improve accuracy by 92%. [62] firstly proposed MMOTU ultrasonic images dataset then used the DS2Net algorithm for feature orientation and semantic segmentation and got 80% results. In [63] used cross-sectional dataset HGSOC to introduce the predicted model. The proposed model predicts handcrafted and deep radiomic features and used the CNN model and give better mutation accuracy. [64] calculate the overall survival of ovarian cancer patients when they are serious and for this used a multilayer dataset and find molecular features and get an accuracy of 95%. Table 4 shows some existing deep learning methodologies, datasets, and results on Ovarian cancer detection.

Table 4. Existing Work on Ovarian Cancer Detection

References	Ovarian Cancer Biomarker	Method	Results
[55]	To diagnose malignancy and to predict molecular subtypes	Deep Interactive Learning with a pre-trained segmentation model	0.74 intersection over union, 0.86 recall, and 0.84 precision
[56]	Ovarian tumor segmentation from ovarian ultrasound image	CNN-based segmentation model, combining GLCM-contourlet transformation (CT) and CNN features	
[57]	Ovarian cancer patient's therapeutic response to bevacizumab should be predicted using histopathological hematoxylin and eosinstained complete sheet images without using any selectively identified regions supplied by the physician.	weakly supervised deep learning approaches	0.882±0.06 accuracy, 0.921±0.04 precision, 0.912±0.03 recall, 0.917 ± 0.07 F-measure
[58]	Segmentation of high-grade serous ovarian cancer with complete automation	Segmentation of Cancer on CTI using DL	Mean DSC performance is approximately 50% on BRAST and Apollo and TCGA

[59]	To improve the accuracy of ovarian cancer detection and the quality of the original MRI images	a deep learning-based ovarian cancer or detection (IEDL-OVD) algorithm for an intelligent IE.	0.735 precision rate and 0.612 recall rate
[61]	A computerized diagnostic model is developed to characterize the ovarian cyst at its early stage to avoid unnecessary biopsy and patient anxiety.	Local Binary Pattern (LBP) textural features and SVM is used to classify the ovarian cyst or mass as benign or malignant from transvaginal 2D B mode ovarian mass ultrasound images	The average accuracy of 92%
[62]	To perform semantic segmentation on MMOTU (Multi-Modality Ovarian Tumor Ultrasound) image data	DS2Net (dual-scheme domain selected network) architecture known as feature orientation is used to perform semantic segmentation	Semantic segmentation value of approximately 80% and 69.81% IoU and 80.86% mIoU
[63]	A cross-sectional dataset of HGSOC (high-grade serous ovarian cancer) to develop predictive radiomic models for early relapse and BRCA mutation	Dedicated software (MODDICOM) is used to extract Hand-crafted features and then a devoted CNN is used to predict BRCA mutation	0.74 AUC for BRCA mutation
[64]	To calculate OS (overall survival) in ovarian cancer with HGS (high-grade serous).	Multilayer omics datasets and histopathological image characteristics to identify molecular features.	Existence differences (HR =18.23, $p < 0.001$), and Accuracy for different classes are more than 95%.

5 CONCLUSION

With the coming of customized medication, the field of ovarian malignancy research has arrived at an interesting junction. A significant part of the quietness of the "quiet executioner" has been dispersed, and late years have seen a flood in the comprehension of the etiology and molecular characteristics of ovarian cancer. Considering these advances, we accept that imaging will assume a focal part in both the preclinical examination and furthermore, the clinical administration of ovarian malignant growth in the years to come. As we have examined, a variety of very interesting imaging methodologies has just a way on clinical consideration, and what's to come is significantly more splendid. In the end, we are idealistic and confident that the blend of technological developments, novel imaging tests, and further combination of imaging into clinical conventions will lead to critical and enduring upgrades in the prognosis and care of ovarian malignant growth patients.

REFERENCES

[1] B. Franier, and M. Thompson, “Early stage detection and screening of ovarian cancer: A research opportunity and significant challenge for biosensor technology,” *Biosens Bioelectron,* vol. 135, pp. 71-81, Jun 15, 2019.

[2] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. J. C. a. c. j. f. c. Forman, “Global cancer statistics,” vol. 61, no. 2, pp. 69-90, 2011.

[3] S. Vaughan, J. I. Coward, R. C. Bast, A. Berchuck, J. S. Berek, J. D. Brenton, G. Coukos, C. C. Crum, R. Drapkin, and D. J. N. R. C. Etemadmoghadam, “Rethinking ovarian cancer: recommendations for improving outcomes,” vol. 11, no. 10, pp. 719-725, 2011.

[4] B. Mughal, M. Sharif, N. Muhammad, T. J. M. r. Saba, and technique, “A novel classification scheme to decline the mortality rate among women due to breast tumor,” vol. 81, no. 2, pp. 171-180, 2018.

[5] R. Siegel, D. Naishadham, and A. J. C. a. c. j. f. c. Jemal, “Cancer statistics, 2012,” vol. 62, no. 1, pp. 10-29, 2012.

[6] A. M. Fayyaz, K. A. Al-Dhlan, S. U. Rehman, M. Raza, W. Mehmood, M. Shafiq, and J.-G. Choi, “Leaf Blights Detection and Classification in Large Scale Applications,” *INTELLIGENT AUTOMATION AND SOFT COMPUTING,* vol. 31, no. 1, pp. 507-522, 2022.

[7] R. Siegel, E. Ward, O. Brawley, and A. J. C. a. c. j. f. c. Jemal, “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths,” vol. 61, no. 4, pp. 212-236, 2011.

[8] J. M. Torpy, A. E. Burke, and R. M. J. J. Golub, “Ovarian cancer,” vol. 305, no. 23, pp. 2484-2484, 2011.

[9] P. Mohaghegh, and A. G. J. R. Rockall, “Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques,” vol. 32, no. 6, pp. 1751-1773, 2012.

[10] A. Sharma, S. Apostolidou, M. Burnell, S. Campbell, M. Habib, A. Gentry-Maharaj, N. Amso, M. Seif, G. Fletcher, N. J. U. i. o. Singh, and gynecology, “Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS),” vol. 40, no. 3, pp. 338-344, 2012.

[11] T. Kaku, S. Ogawa, Y. Kawano, Y. Ohishi, H. Kobayashi, T. Hirakawa, and H. J. M. e. m. Nakano, “Histological classification of ovarian cancer,” vol. 36, no. 1, pp. 9-17, 2003.

[12] S. N. Thomas, B. Friedrich, M. Schnaubelt, D. W. Chan, H. Zhang, and R. J. i. Aebersold, “Orthogonal proteomic platforms and their implications for the stable classification of high-grade serous ovarian cancer subtypes,” pp. 101079, 2020.

[13] A. Muiz Fayyaz, M. Kolivand, J. Alyami, S. Roy, and A. Rehman, "Computer Vision-Based Prognostic Modelling of COVID-19 from Medical Imaging," *Prognostic Models in Healthcare: AI and Statistical Approaches*, pp. 25-45: Springer, 2022.

[14] A. Babaier, and P. J. D. Ghatage, “Mucinous cancer of the ovary: overview and current status,” vol. 10, no. 1, pp. 52, 2020.

[15] S. Liu, Y. Guo, B. Li, H. Zhang, R. Zhang, S. J. C. M. Zheng, and Research, "Analysis of Clinicopathological Features of Cervical Mucinous Adenocarcinoma with a Solitary Ovarian Metastatic Mass as the First Manifestation," vol. 12, pp. 8965, 2020.

[16] P. Krämer, A. Talhouk, M. A. Brett, D. S. Chiu, E. S. Cairns, D. A. Scheunhage, R. F. Hammond, D. Farnell, T. M. Nazeran, and M. J. C. C. R. Grube, "Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma," vol. 26, no. 20, pp. 5400-5410, 2020.

[17] J. E. Steffen, T. Tran, M. Yimam, K. M. Clancy, T. B. Bird, M. Rigler, W. Longo, D. S. J. J. o. O. Egilman, and E. Medicine, "Serous ovarian cancer caused by exposure to asbestos and fibrous talc in cosmetic talc powders—A case series," vol. 62, no. 2, pp. e65-e77, 2020.

[18] H. Assem, P. F. Rambau, S. Lee, T. Ogilvie, A. Sienko, L. E. Kelemen, and M. J. T. A. j. o. s. p. Köbel, "High-grade Endometrioid Carcinoma of the Ovary," vol. 42, no. 4, pp. 534-544, 2018.

[19] M. H. Roh, Y. Yassin, A. Miron, K. K. Mehra, M. Mehrad, N. M. Monte, G. L. Mutter, M. R. Nucci, G. Ning, and F. D. J. M. P. Mckeon, "High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression," vol. 23, no. 10, pp. 1316-1324, 2010.

[20] C. B. Gilks, B. A. Clarke, G. Han, M. Köbel, T. Longacre, W. G. McCluggage, J. D. Seidman, P. Shaw, and R. A. J. M. P. Soslow, "Letter to the editor regarding 'Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression'," vol. 24, no. 9, pp. 1281-1282, 2011.

[21] M. Köbel, S. E. Kalloger, N. Boyd, S. McKinney, E. Mehl, C. Palmer, S. Leung, N. J. Bowen, D. N. Ionescu, and A. J. P. m. Rajput, "Ovarian carcinoma subtypes are different diseases: implications for biomarker studies," vol. 5, no. 12, pp. e232, 2008.

[22] C. P. J. M. O. Crum, "Intercepting pelvic cancer in the distal fallopian tube: theories and realities," vol. 3, no. 2, pp. 165-170, 2009.

[23] C. B. Gilks, J. Irving, M. Köbel, C. Lee, N. Singh, N. Wilkinson, and W. G. J. T. A. j. o. s. p. McCluggage, "Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas," vol. 39, no. 3, pp. 357-364, 2015.

[24] M. S. Anglesio, A. Bashashati, Y. K. Wang, J. Senz, G. Ha, W. Yang, M. R. Aniba, L. M. Prentice, H. Farahani, and H. J. T. J. o. p. Li Chang, "Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden," vol. 236, no. 2, pp. 201-209, 2015.

[25] N. Kato, S.-i. Sasou, and T. J. M. P. Motoyama, "Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary," vol. 19, no. 1, pp. 83-89, 2006.

[26] P. Vercellini, F. Parazzini, G. Bolis, S. Carinelli, M. Dindelli, N. Vendola, L. Luchini, P. G. J. A. J. o. O. Crosignani, and Gynecology, "Endometriosis and ovarian cancer," vol. 169, no. 1, pp. 181-182, 1993.

[27] J. A. Rauh-Hain, W. B. Growdon, N. Rodriguez, A. Goodman, D. M. Boruta II, J. O. Schorge, N. S. Horowitz, and M. G. J. G. o. Del Carmen, "Carcinosarcoma of the ovary: a case–control study," vol. 121, no. 3, pp. 477-481, 2011.

[28] D. Berton-Rigaud, M. Devouassoux-Shisheboran, J. A. Ledermann, M. M. Leitao, M. A. Powell, A. Poveda, P. Beale, R. M. Glasspool, C. L. Creutzberg, and P. J. I. J. o. G. C. Harter, "Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma," vol. 24, no. Supp 3, 2014.

[29] M. G. del Carmen, M. Birrer, and J. O. J. G. o. Schorge, "Carcinosarcoma of the ovary: a review of the literature," vol. 125, no. 1, pp. 271-277, 2012.

[30] J. A. Rauh-Hain, E. J. Diver, J. T. Clemmer, L. S. Bradford, R. M. Clark, W. B. Growdon, A. Goodman, D. M. Boruta II, J. O. Schorge, and M. G. J. G. o. Del Carmen, "Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis," vol. 131, no. 1, pp. 46-51, 2013.

[31] R. H. Ali, J. D. Seidman, M. Luk, S. Kalloger, and C. B. J. I. j. o. g. p. Gilks, "Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor," vol. 31, no. 6, pp. 499-506, 2012.

[32] M. Carcangiu, R. J. Kurman, M. L. Carcangiu, and C. S. Herrington, *WHO classification of tumours of female reproductive organs*: International Agency for Research on Cancer, 2014.

[33] S. K. Sharma, B. Nemieboka, E. Sala, J. S. Lewis, and B. M. J. J. o. N. M. Zeglis, "Molecular imaging of ovarian cancer," vol. 57, no. 6, pp. 827-833, 2016.

[34] L. Valentin, L. Ameye, A. Testa, F. Lécuru, J.-P. Bernard, D. Paladini, S. Van Huffel, and D. J. G. o. Timmerman, "Ultrasound characteristics of different types of adnexal malignancies," vol. 102, no. 1, pp. 41-48, 2006.

[35] M. Yasmin, M. Sharif, S. Masood, M. Raza, and S. J. W. A. S. J. Mohsin, "Brain image reconstruction: A short survey," vol. 19, no. 1, pp. 52-62, 2012.

[36] M. Yasmin, M. Sharif, and S. J. R. J. o. R. S. Mohsin, "Survey paper on diagnosis of breast cancer using image processing techniques," vol. 2277, pp. 2502, 2013.

[37] M. A. Khan, I. U. Lali, A. Rehman, M. Ishaq, M. Sharif, T. Saba, S. Zahoor, T. J. M. r. Akram, and technique, "Brain tumor detection and classification: A framework of marker-based watershed algorithm and multilevel priority features selection," vol. 82, no. 6, pp. 909-922, 2019.

[38] M. Yasmin, M. Sharif, S. Masood, M. Raza, and S. J. W. A. S. J. Mohsin, "Brain image enhancement-A survey," vol. 17, no. 9, pp. 1192-1204, 2012.

[39] M. Sharif, U. Tanvir, E. U. Munir, M. A. Khan, M. J. J. o. A. I. Yasmin, and H. Computing, "Brain tumor segmentation and classification by improved binomial thresholding and multi-features selection," pp. 1-20, 2018.

[40] S. Sohaib, T. Mills, A. Sahdev, J. Webb, P. Vantrappen, I. Jacobs, and R. J. C. r. Reznek, "The role of magnetic resonance imaging and ultrasound in patients with adnexal masses," vol. 60, no. 3, pp. 340-348, 2005.

[41] J. Amin, M. Sharif, M. A. Anjum, M. Raza, and S. A. C. Bukhari, "Convolutional neural network with batch normalization for glioma and stroke lesion detection using MRI," *Cognitive Systems Research*, vol. 59, pp. 304-311, 2020.

[42] B. De La Franier, M. J. B. Thompson, and Bioelectronics, "Early stage detection and screening of ovarian cancer: A research opportunity and significant challenge for biosensor technology," vol. 135, pp. 71-81, 2019.

[43] B. Aktas, S. Kasimir-Bauer, P. Wimberger, R. Kimmig, and M. J. A. r. Heubner, "Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer," vol. 33, no. 1, pp. 329-336, 2013.

[44] E. Kobayashi, Y. Ueda, S. Matsuzaki, T. Yokoyama, T. Kimura, K. Yoshino, M. Fujita, T. Kimura, T. J. C. E. Enomoto, and P. Biomarkers, "Biomarkers for screening, diagnosis, and monitoring of ovarian cancer," vol. 21, no. 11, pp. 1902-1912, 2012.

[45] F. Su, J. Lang, A. Kumar, C. Ng, B. Hsieh, M. A. Suchard, S. T. Reddy, and R. J. B. i. Farias-Eisner, "Validation of candidate serum ovarian cancer biomarkers for early detection," vol. 2, pp. 117727190700200011, 2007.

[46] D. G. Peters, D. M. Kudla, J. A. DeLoia, T. J. Chu, L. Fairfull, R. P. Edwards, R. E. J. C. E. Ferrell, and P. Biomarkers, "Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression," vol. 14, no. 7, pp. 1717-1723, 2005.

[47] J.-H. Kim, S. J. Skates, T. Uede, K.-k. Wong, J. O. Schorge, C. M. Feltmate, R. S. Berkowitz, D. W. Cramer, and S. C. J. J. Mok, "Osteopontin as a potential diagnostic biomarker for ovarian cancer," vol. 287, no. 13, pp. 1671-1679, 2002.

[48] Y. Zhang, B. Guo, R. J. A. b. Bi, and biotechnology, "Ovarian cancer: biomarker proteomic diagnosis in progress," vol. 168, no. 4, pp. 910-916, 2012.

[49] S. P. Langdon, G. J. Rabiasz, G. L. Hirst, R. King, R. A. Hawkins, J. F. Smyth, and W. R. J. C. C. R. Miller, "Expression of the heat shock protein HSP27 in human ovarian cancer," vol. 1, no. 12, pp. 1603-1609, 1995.

[50] K. L. Abbott, J. M. Lim, L. Wells, B. B. Benigno, J. F. McDonald, and M. J. P. Pierce, "Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis," vol. 10, no. 3, pp. 470-481, 2010.

[51] Y. Xu, Z. Shen, D. W. Wiper, M. Wu, R. E. Morton, P. Elson, A. W. Kennedy, J. Belinson, M. Markman, and G. J. J. Casey, "Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers," vol. 280, no. 8, pp. 719-723, 1998.

[52] I. Sedláková, J. Vávrová, J. Tošner, and L. J. T. B. Hanousek, "Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer," vol. 32, no. 2, pp. 311-316, 2011.

[53] O. Onen, A. Sisman, N. D. Gallant, P. Kruk, and R. J. S. Guldiken, "A urinary Bcl-2 surface acoustic wave biosensor for early ovarian cancer detection," vol. 12, no. 6, pp. 7423-7437, 2012.

[54] R. Guldiken, P. Kruk, N. Gallant, A. Sisman, and O. Onen, "A urinary Bcl-2 surface acoustic wave biosensor for early ovarian cancer detection," 2012.

[55] D. J. Ho, M. H. Chui, C. M. Vanderbilt, J. Jung, M. E. Robson, C.-S. Park, J. Roh, and T. J. Fuchs, "Deep Interactive Learning-based ovarian cancer segmentation of H&E-stained whole slide images to study morphological patterns of BRCA mutation," *arXiv preprint arXiv:2203.15015*, 2022.

[56] K. Srilatha, F. Jayasudha, M. Sumathi, and P. Chitra, "Automated Ultrasound Ovarian Tumour Segmentation and Classification Based on Deep Learning Techniques," *Advances in Electrical and Computer Technologies*, pp. 59-70: Springer, 2022.

[57] C.-W. Wang, C.-C. Chang, Y.-C. Lee, Y.-J. Lin, S.-C. Lo, P.-C. Hsu, Y.-A. Liou, C.-H. Wang, and T.-K. Chao, "Weakly supervised deep learning for prediction of treatment effectiveness on ovarian cancer from histopathology images," *Computerized Medical Imaging and Graphics*, vol. 99, pp. 102093, 2022.

[58] T. Buddenkotte, "Fully Automated Segmentation of High Grade Serous Ovarian Cancer on Computed Tomography Images using Deep Learning," University of Cambridge, 2022.

[59] M. Jeya Sundari, and N. Brintha, "An Intelligent Black Widow Optimization on Image Enhancement with Deep Learning Based Ovarian Tumor Diagnosis model," *Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization*, pp. 1-8, 2022.

[60] D. Mikdadi, K. A. O'Connell, P. J. Meacham, M. A. Dugan, M. O. Ojiere, T. B. Carlson, and J. A. Klenk, "Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery," *Cancer Biomarkers*, vol. 33, no. 2, pp. 173-184, 2022.

[61] S. Sheela, and M. Sumathi, "An Evaluation of Effectiveness of a Texture Feature Based Computerized Diagnostic Model in Classifying the Ovarian Cyst as Benign and Malignant from Static 2D B-Mode Ultrasound Images," *Current Medical Imaging*, 2022.

[62] Q. Zhao, S. Lyu, W. Bai, L. Cai, B. Liu, M. Wu, X. Sang, M. Yang, and L. Chen, "A Multi-Modality Ovarian Tumor Ultrasound Image Dataset for Unsupervised Cross-Domain Semantic Segmentation," *arXiv preprint arXiv:2207.06799*, 2022.

[63] G. Avesani, H. E. Tran, G. Cammarata, F. Botta, S. Raimondi, L. Russo, S. Persiani, M. Bonatti, T. Tagliaferri, and M. Dolciami, "CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset," *Cancers*, vol. 14, no. 11, pp. 2739, 2022.

[64] H. Zeng, L. Chen, M. Zhang, Y. Luo, and X. Ma, "Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer," *Gynecologic Oncology*, vol. 163, no. 1, pp. 171-180, 2021.